menu
    • menu
    [{"orgOrder":0,"company":"Microbion","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ CARB-X","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ CARB-X"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"US Navy","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Podiatry","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ US Navy","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ US Navy"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Suspension","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Microbion \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"Microbion \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Microbion \/ Inapplicable"},{"orgOrder":0,"company":"Microbion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pravibismane","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Microbion","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Suspension for Inhalation","sponsorNew":"Microbion \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Microbion \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Pravibismane

    Menu

    Pravibismane

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Podiatry

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Microbion Reports Positive Phase 2 Pravibismane Data for Diabetic Foot Ulcers

    Details : Microbion's lead drug candidate, MBN-101 (pravibismane), is the first product in this new class and has multiple novel modes of action, being developed for diabetic foot ulcer infections (DFI).

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 13, 2024

    Lead Product(s) : Pravibismane

    Therapeutic Area : Podiatry

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Microbion's Pravibismane Granted Second FDA Orphan Drug Designation for NTM Infections

    Details : MBN 101 (Pravibismane) is a small molecule antibacterial agent which is being evaluated in preclinical trials for the treatment of non-tuberculous mycobacterial (NTM) infections.

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 30, 2024

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Podiatry

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic F...

    Details : MBN-101 (pravibismane) is the first in a new class of anti-infective drugs demonstrating broad-spectrum potency against a wide range of multidrug-resistant bacteria, and biofilms ubiquitous in DFU infections.

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    September 03, 2023

    Lead Product(s) : Pravibismane

    Therapeutic Area : Podiatry

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Microbion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections

    Details : MBN-101 (inhaled pravibismane) has received QIDP, Fast Track and Orphan drug designation from the USFDA for the treatment of pulmonary infections in patients with cystic fibrosis. Microbion has successfully completed non-clinical studies for the inhaled ...

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 04, 2023

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Microbion Corporation Announces Data Highlighting Pravibismane's Effect on Bacterial Energetics Presented at A...

    Details : MBN-101 has been granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation by the US FDA for: (1) adjunctive treatment of moderate and severe diabetic foot ulcer infection; and (2) treatment of post-surgical orthopedic im...

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 10, 2022

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Podiatry

    Study Phase : Phase II

    Sponsor : US Navy

    Deal Size : $2.1 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBR...

    Details : Pravibismane (MBN-101), is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacteri...

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    July 06, 2022

    Lead Product(s) : Pravibismane

    Therapeutic Area : Podiatry

    Highest Development Status : Phase II

    Sponsor : US Navy

    Deal Size : $2.1 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Podiatry

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane

    Details : Pravibismane (MBN-101) shuts down bacterial ATP production thereby halting global bacterial cellular metabolism. Pravibismane exhibits broad-spectrum, potent in vitro activity against pathogens and their biofilms including MRSA, CRE, and multidrug resist...

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    April 10, 2022

    Lead Product(s) : Pravibismane

    Therapeutic Area : Podiatry

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Microbion Corporation Announces Poster Highlighting Pravibismane Activity Against Common Cystic Fibrosis Pulmo...

    Details : MBN-101 (pravibismane) is first new class of anti-infective drugs with novel MOA, rapidly reduces bacterial ATP production in both planktonic and biofilm bacterial populations, thereby halting global bacterial cellular metabolism.

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 11, 2022

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Microbion Corporation Announces Data Highlighting In Vitro Activity of Pravibismane in NTM, including Activity...

    Details : MBN-101 (pravibismane) is first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial ce...

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    January 06, 2022

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed

    Microbion

    U.S.A arrow
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : IND Enabling

    Sponsor : Cystic Fibrosis Foundation

    Deal Size : $7.4 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Microbion Corporation Receives Additional Funding Support from the Cystic Fibrosis Foundation to Speed Advance...

    Details : This new funding of up to $1.8 million will directly support IND-enabling toxicology studies of pravibismane and is in addition to $5.6 million previously awarded by the Foundation, for a combined total of up to $7.4 million.

    Product Name : MBN-101

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    February 22, 2021

    Lead Product(s) : Pravibismane

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : IND Enabling

    Sponsor : Cystic Fibrosis Foundation

    Deal Size : $7.4 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth